A Novel Serum Exosomal miRNA Signature in the Early Prediction of Persistent Organ Failure in Patients with Acute Pancreatitis

Lei Li,Qichen Zhang,Yongpu Feng,Fanyang Kong,Fengyuan Sun,Pei Xie,Jiangman Zhao,Hang Yu,Jiahuan Zhou,Shouxin Wu,Shengbing Zhao,Zhaoshen Li,Feng Liu,Yiqi Du,Xiangyu Kong
DOI: https://doi.org/10.1097/sla.0000000000006229
IF: 13.787
2024-02-07
Annals of Surgery
Abstract:Objective: Current study aims to investigate whether serum exosomal microRNAs (miRNAs) could be potential biomarkers in predicting APs with POF at early phase. Background: Novel biomarkers are sorely needed for early prediction of persistent organ failure (POF) in acute pancreatitis (AP) patients. Methods: In the discovery stage, exosomal miRNAs were profiled in sera from APs with or without POF (5 vs. 5) using microarrays. POF-associated miRNA signatures then were assessed in training cohort (n=227) and further validated in three independent cohorts (n=516), including one nested case-control cohort. Results: A total of 743 APs were recruited in this large-scale biomarker identification study with a nested case-control study. Data from the discovery cohort demonstrated that 90 exosomal miRNAs were significantly dysregulated in APs with POF compared with controls. One miRNA classifier (Cmi) comprising 3 miRNAs (miR-4265, 1208, 3127-5p) was identified in the training cohort, and was further evaluated in two validation cohorts for their predictive value for POF. AUCs for Cmi ranged from 0.88 to 0.90, which was statistically superior to AUCs of APACHE-II and BISAP, and outperformed BUN and creatinine in POF prediction across all cohorts ( P <.05). Higher levels of Cmi indicated increased need for ICU admission, prolonged hospitalization, and elevated mortality rate, thus poor prognosis. In the nested case-control study, Cmi could help identify prediagnostic POF in post-ERCP pancreatitis cases within “golden hours” after ERCP with high efficacy. Conclusions: Serum exosomal Cmi may be an early predictor for POF in AP, even within “golden hours” after AP onset. Trial registration: ClinicalTrials.gov (NCT02602808)
surgery
What problem does this paper attempt to address?